Nasdaq

Processa Pharmaceuticals Provides Portfolio and Business Update

VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...
Seeking Alpha

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided ...

Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance

Detailed price information for Processa Pharmaceuticals Inc (PCSA-Q) from The Globe and Mail including charting and trades.
Seeking Alpha

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of ...
WATE 6 On Your Side

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc. research and ratings by Barron's. View PCSA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
USA Today

Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small ...
Nasdaq

Processa Pharmaceuticals (PCSA) Price Target Increased by 2,400.00% to 25.50

The average one-year price target for Processa Pharmaceuticals (NasdaqCM:PCSA) has been revised to $25.50 / share. This is an increase of 2,400.00% from the prior estimate of $1.02 dated December 3, ...
Morningstar

Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money (TM) Show on Bloomberg TV | Morningstar

David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's ...
USA Today

Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the ...
Detroit Free Press

Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company’s ...